about
Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureusActivity of Bay y3118 against quinolone-susceptible and -resistant gram-negative and gram-positive bacteria.Antimicrobial susceptibility of coagulase-negative staphylococci.In vitro activities of enoxacin, enrofloxacin, sparfloxacin, and ciprofloxacin against Escherichia coli strains isolated from diarrheic lambs and kids.The prophylaxis of bacterial infections in neutropenic patients.Vancomycin-resistant enterococci.In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects.In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.In vitro and in vivo antibacterial efficacies of CFC-222, a new fluoroquinolone.Current perspectives on glycopeptide resistance.In vitro activity and rodent efficacy of clinafloxacin for bovine and swine respiratory disease.Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.Accumulation of norfloxacin by Mycobacterium aurum and Mycobacterium smegmatis.Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis.Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.NorA plasmid resistance to fluoroquinolones: role of copy number and norA frameshift mutations.Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper.Fluoroquinolones in animal health.Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-methyl-4-methylaminopiperidin-1-yl)-fluoroquinolone derivatives.Bactericidal effect of sparfloxacin alone and in combination with amoxicillin against Streptococcus pneumoniae as determined by kill-kinetic studies.Antimicrobial activity of enrofloxacin against Staphylococcus intermedius strains isolated from canine pyodermas.Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci.Antimicrobial drug susceptibility of Staphylococcus intermedius clinical isolates from canine pyoderma.In vitro extracellular and intracellular activity of two newer and two earlier fluoroquinolones against Listeria monocytogenes.
P2860
Q28379074-84FCA1AE-F2FB-43AA-B646-A4AEE40E7740Q33750357-54CCC030-2F6D-442E-9070-11AD4C94883FQ33760227-2DC6EAED-837F-41FF-AE75-429364E4D8B8Q33762012-0E83B34E-81AE-442F-9017-2F9771A0CF0CQ33769354-C7CEDA71-D243-4A29-8F50-0D42CF168FFDQ33975592-8565B62E-7F34-4D06-AB80-027E7C8905BAQ33976279-E6C8212B-0138-4762-AA7B-1B6F858A19ACQ33978324-AAF76E54-5625-4866-99EA-B9F4F8F204FBQ33983727-E77D9DC1-156F-4A86-AD6A-AA088C9869F3Q34739682-1BE4BD6E-4B67-4757-BA72-9527E164E346Q35125320-BCE7BC64-228A-494B-BEAB-396B1B2D7050Q35137355-4F53FA55-B58A-4778-9C93-D26828451B7BQ35138544-E0D471EF-E085-45D4-925C-A2E8B51B5B60Q35368590-044C5D71-48D8-4D9C-AACC-662C292E55C9Q36927802-E8EB8493-484B-40F6-9771-44E4FCEDA23FQ39469535-9D071A72-84BC-4781-8F52-25BBC67D3F77Q39470064-158C7ADF-D8AC-40E5-B472-C639DA56BE44Q39472798-E3B1D3B5-007B-416B-854B-24A2B08643A2Q39474505-D4E7DFA0-869B-4B8A-AB21-ACDEE07C16B7Q39537237-006CB8B2-B920-4CDE-8A5B-E1F85EC15A8CQ39557385-9DD9E533-F592-4CA1-A6A3-A1D99F2F7922Q39558184-33AF7028-E622-4BD3-9B85-1739B69E7E75Q39559768-C895CB14-A421-46F2-84C7-6593BEA4A83AQ39651324-54E51833-CBE2-4D5C-A8DF-D92E9C094EA1Q39782439-B138DAD1-D4A8-49DB-B143-A3BF08819998Q39782937-CE59F55A-3DFC-4405-B433-318597B483CFQ39783715-68FE1399-0AED-420B-88E0-DAE4ABD87FFFQ39841944-AF52AAE1-9352-481C-8147-0C0EBA15D937Q40667218-6B59EABC-1BB5-429B-90C7-9DDAE02D7BC7Q41306010-FAADEF0C-FF61-4D94-893E-2E43EC000D01Q43148567-6B9FCD35-8DBB-4712-91B3-119806FB4318Q43580576-66FB211E-D38A-4227-9A70-840DAF7A00E8Q43649516-1BAF26B5-3DA8-4EFF-8B4D-15BC61AB0A32Q44959765-9F86E39A-3BCA-4FBE-A1FC-9252DABA1FAFQ45259098-D8F9E37D-0DF6-45B2-8FF4-74D8E0F80C5AQ54148829-FE913F03-CA6E-471D-BBF0-E7A022A21AD5
P2860
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
New quinolones and gram-positive bacteria.
@en
type
label
New quinolones and gram-positive bacteria.
@en
prefLabel
New quinolones and gram-positive bacteria.
@en
P2860
P356
P1476
New quinolones and gram-positive bacteria.
@en
P2093
Piddock LJ
P2860
P304
P356
10.1128/AAC.38.2.163
P407
P577
1994-02-01T00:00:00Z